Patient P-01573
Therapy response
Stable
Tolerance
Deteriorating
GI state
Improving
Inflammatory state
Improving
Nutritional resilience
Stable
Discontinuation risk
67%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 31 NP-02 recommended — Dietary Support Protocol NP-02
- Day 32 Patient accepted — Started NP-02 in the companion
- Day 42 GI symptom burden −12% vs expected — Dietary Support Protocol NP-02
- Day 43 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 48 Tolerance state changed — Unstable → Improving
- Day 60 GI-04 recommended — GI Support Protocol GI-04
- Day 61 Patient accepted — Started GI-04 in the companion
- Day 69 GI symptom burden −26% vs expected — GI Support Protocol GI-04
- Day 75 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 43.
Primary contributors, last 14 days
- Toxicity+10
- GI instability-7
- Inflammatory activity-6
- Nutritional resilience+4
- Treatment adherence-4
What helped?
- Dietary Support Protocol NP-02Day 31Result: symptom burden −12%
- GI Support Protocol GI-04Day 60Result: symptom burden −26%
LIFE OS recommendation
Monitoring Escalation ME-01
76%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 100% showed improvement
- median effect visible after 3 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 50 and rising
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 25/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Inflammatory signalling ↓65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 49
- WearableHRV 20 ms, trending down
- Drug metabolism and exposure ↑20
- BloodToxicity index 47
- Autonomic recovery ↑20
- Wearable1,021 steps/day
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 2.9 · butyrate capacity 25/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 22 ms
- Sleep
- 7.3 h
- Steps
- 1,621
- Resting HR
- 71 bpm
Daily log: GI score 50, nutritional resilience 43, adherence 46.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01879 | 63% | S14 | SC-12 | improved | 51 |
| P-01364 | 58% | S14 | GI-04 | improved | 49 |
| P-01462 | 58% | S14 | NP-02 | improved | 47 |
| P-01409 | 56% | S14 | SC-12 | improved | 41 |
| P-01496 | 56% | S14 | SC-12 | improved | 46 |
| P-01661 | 54% | S03 | GI-04 | improved | 52 |
| P-01775 | 54% | S14 | SC-12 | improved | 48 |
| P-01624 | 53% | S14 | GI-04 | improved | 52 |
| P-01872 | 53% | S14 | NP-02 | improved | 47 |
| P-01330 | 52% | S14 | GI-04 | improved | 47 |
| P-01339 | 52% | S14 | GI-04 | improved | 54 |
| P-01393 | 52% | S14 | GI-04 | improved | 53 |